PRESS-RELEASE ·Filed Mar 3, 2026

VXRT

Vaxart, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed7mo ago WireGlobeNewswire
Press release: earnings
Actionable Insight • Neutral

Traders should monitor the March 12 earnings call for potential updates on cash runway, clinical progress, or funding developments, which could impact the stock given Vaxart's clinical-stage status and history of dilution risk.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
VXRT ▼ -13.16% at T+60d
NEUTRAL call ✗ call lost -13.16% · α vs SPY -23.25% · entry $0.7600 → $0.6600
Entry anchored
Mar 3, 2026
via day open
T+1d
-5.26%
call -5.26% · α -4.69%
$0.7200
settled 7mo ago
T+5d
+1.32%
call +1.32% · α +2.65%
$0.7700
settled 7mo ago
T+20d
-17.11%
call -17.11% · α -12.69%
$0.6300
settled 6mo ago
T+60d
-13.16%
call -13.16% · α -23.25%
$0.6600
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

Vaxart, Inc. announced upcoming webcast events to discuss its full-year 2025 financial results and provide a stockholder update. The earnings call is scheduled for March 12, 2026, after market close, followed by a stockholder fireside chat on March 13, 2026. No financial results or material updates were released in this announcement.

Key Facts

  • Vaxart will report full-year 2025 financial results on March 12, 2026, after market close.
  • A conference call and webcast will be held the same day at 4:30 p.m. ET.
  • A stockholder fireside chat is scheduled for March 13, 2026, at 4:30 p.m. ET.
  • No financial data or operational updates were disclosed in this press release.
  • Replays of both events will be available on the company's website.

Financial Impact

No financial impact from this announcement; actual results to be disclosed on March 12.

Risk Factors

  • High volatility expected around earnings announcement due to lack of transparency ahead of the call.
  • Potential for dilutive financing or extended cash runway concerns given Vaxart's pre-revenue biotech profile.

Market Snapshot

Exchange
OTC

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3248893
21 reports for VXRT
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+60▲ +37.66%May 1, 2026
Filters
Rows
Reports for VXRT — sortable, filterable
TypeNow
Jul 28, 2026
9w ago
8-K
NEUTRAL ★ 2/10
$0.4800 $0.5000▲ +4.17%▲ +0.79%$0.4400 (−8.33%)
Jul 7, 2026
12w ago
8-K
NEUTRAL ★ 4/10
$0.5500 $0.6000▲ +9.09%▲ +5.93%$0.4400 (−20.00%)
Jul 6, 2026
12w ago
DEFA14A
NEUTRAL ★ 5/10
$0.6200 $0.5900▼ −4.84%▼ −5.69%$0.4400 (−29.03%)
Jul 2, 2026
13w ago
DEFA14A
BULLISH ★ 5/10
$0.6400 $0.5490▼ −14.22%▼ −14.52%$0.4400 (−31.25%)
Jul 2, 2026
13w ago
8-K
NEUTRAL ★ 4/10
$0.6400 $0.5200▼ −18.75%▼ −18.34%$0.4400 (−31.25%)
Jun 26, 2026
13w ago
DEFA14A
NEUTRAL ★ 4/10
$0.5700 $0.4501▼ −21.04%▼ −20.78%$0.4400 (−22.81%)
Jun 26, 2026
13w ago
DEFA14A
NEUTRAL ★ 3/10
$0.5700 $0.4501▼ −21.04%▼ −20.78%$0.4400 (−22.81%)
Jun 26, 2026
13w ago
8-K
MIXED ★ 5/10
$0.5700 $0.4501▼ −21.04%▼ −20.78%$0.4400 (−22.81%)
Jun 16, 2026
15w ago
DEFA14A
NEUTRAL ★ 3/10
$0.5600 $0.5300▼ −5.36%▼ −6.21%$0.4400 (−21.43%)
Jun 8, 2026
16w ago
DEFA14A
NEUTRAL ★ 4/10
$0.5800 $0.5502▼ −5.14%▼ −6.53%$0.4400 (−24.14%)
Showing 10 of 21

US Market Status

Market Open — Closes in 52m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Mar 3, 2026